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selected rings endothelium was rubbed. Rings were mounted in an organ bath chamber 
and prewntracted with potassium chloride. Responses of prawntraded IMA rings to 
increasing dose of sertraline (lo’-1OsMol.L~‘) were compared with vehicle. Relaxations 
were expressed as a percentage of precontraction. 
Secondly, we assessed dose-response curves of phenylephrine (10.‘-1O~sMol.L”) in the 
absence or presence of serlraline (105Mol.L~>. 
Results: Sertraline induced concentration-dependent vasodllation (p<O.Ol; repeated 
measures ANOVA combined with post-hoc t-statistics), which was profound in nature 
(maximal dilatory effects exceeding 100% in the concentration-range used). There were 
no significant differences between rubbed and unrubbed rings,, thus vasodilation was 
independent of the endothelium. Presence of sertraline markedly attenuated contractile 
responses to phenylephrine. resulting in a significant rightward shift of the concentration- 
response curve (~~0.05). 
Conclusion: Our results suggest that sertraline may be protective against arterial vasos- 
pasm in depressive post-CABG patients. Vasodilatory properties of sertraline may have 
important clinical implications in the use of SSRls. 
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1203-l 23 Hypertension Adverse Experiences Among 
Osteoarthritis Patients Treated With Rofecoxib, 
Celecoxib, or Acetaminophen in the VACT Trials 
Greoow P. Geba, Adam 8. Polis, Richard A. Petruschke, William F. Keane, Merck 8. Co., 
Inc., West Point, PA 
Background: Inhibition of cyclooxygenase (COX)-2 may alter renal function in some 
patients due to effects on renal blood flow and tubular function. We evaluated hyperten- 
sion adverse experiences (AEs) in patients treated with the COX-2 specific inhibitors, 
rofecoxib and celecoxib compared to acetaminophen. Melhods: A total of 1960 patients 
(VACT 1, N=381 and VACT 2. N=l579) with osteoarthritis of the knee were enrolled in 
two randomized. double-blind, active comparator efficacy trials. The patients received 
treatment with rofecoxib 12.5 mg (N=355) or 25 mg (N=622). celecoxib 200 mg (N=620), 
or acetaminophen 4000 mg (N=363) daily for 6 weeks. Patient demographics were simi- 
lar across treatment groups in both studies. The majority of patients were Cauoaslan 
(87%), women (68%), with a median age of 62 years. An exploratory analysis was per- 
formed to evaluate the percentage of patients with hypertension-related AEs and dlscon- 
tinuations due to hypertension-related AEs. Hypertension-related AEs were dominated 
by the term hypertension, but included all terms that implied hypertension. Results: 
Overall, 38 (1.9%) patients experienced an hypertension-related AE. The percentage of 
patients by treatment group was rofecoxib 12.5 mg, 2.8% (10 patients); rofecoxib 25 mg, 
1.3% (8 patients); celecoxib 200 mg, 1.8% (11 patients); and acetaminophen 4000 mg, 
2.5% (9 patients). The percentage for all rofecoxib patients was 1.8%. Less than 1% of 
the patients in each treatment group discontinued the studies due to a hypertension- 
related AE. No clinically meaningful difference in mean change from baseline in blood 
pressure was observed when comparing rofecoxlb at both doses to celecoxib 01 acetami- 
nophen. Conclusion: The percentage of patients with hypertension-related AEs was 
small. Although not a prespeclfied analysis, we observed comparable incidence of hyper- 
tension-related AEs comparing rofecoxlb and celecoxib. Patients treated with COX-2 
inhibitors were at no greater risk to experience a hypertension-related AE than those 
treated with acetaminophen. 
1203-124 Prevention of Renal Fibrosis With Dual ACE+NEP 
Inhibition With MDL 100,240 in a Transgenic Model of 
Angiotensin II-Dependent Hypertension 
Valeria Valdisolo, Anna Sandra Belloni. Diego Guidolin, Achille Cesare Pessina, Gian 
Paolo Rossi, Clin Med 4, Padova, Italy, University of Padua, Padova, Italy 
BACKGROUND. Dual ACE+NEP inhibition is being proposed as a novel therapeutic 
strategy in cardiovascular disease. As NEP is involved in the degradation of vasodllatory 
and growth-inhibitory peptides, like ANP. BNP, adrenomedullin and bradykinin, and is 
mainly expressed in the kidney epithelial brush border, dual ACE+NEP Inhibition might 
have peculiar nephroprotective effects. 
METHODS. To verify this hypothesis we randomly allocated male heterozygous RenP 
transgemc rat (TGR(Ren2)27), a model of prominent cardiovascular disease, to receive a 
placebo, MDL 100,240 (40 mg/Kg ) or ramipril(5 mg/Kg ) by gavage for 8 weeks. After 4 
week the bradykinin 4 receptor antagonist icatibant (0.5 mg/Kg) was administered 
(osmotic minipumps) to 50% of rats receiving MDL 100,240 or ramipril. At the end of 
treatment, glomerular density (GD), volume (GV), fibrosis (GF) and tubulointerstitial fibro- 
sis (TF) were measured by PC-assisted histomorphometry on Masson’s trichrome- and 
Sirius Red- stained cryosections with a specific software (Leica QwinTM). 
RESULTS. Compared with placebo, MDL 100,240 decreased blood pressure (from 
251+24 to 137t6 mmHg, pO.001) being as effective as ramipril (127r4). TF was signifi- 
cantly reduced (from 13tl% in placebo, m * SEM) in MDL 100,240 (to 9*1%, p=O.O03) 
and in ramipril (to 9+1%. p=O.O03) treated rats. At variance, GD, GV and GF were not 
affected. lcatibant significantly (p=O.OOl) blunted the lowenng of TF in both MDL 100,240 
(13*1%) and ramipril (13+1%) treated rats. 
CONCLUSION. 1) Enhancement of bradykinin. via 8, receptor, plays a relevant role In 
the nephroprotective effects of both MDL 100,240 and tamipril; 2) TF appear to preced 
GF. GD and GV and therefore may be an accurate index for estimating early renal dam- 
age in TGR(Ren2)27. 
1203-l 25 Effects of Valsartan and Valery1 4-Hydroxy Valsarlan on 
Human Platelets: A Possible Missing Link to Explain 
Reduction of Acute Vascular Events With Angiotensin II 
Receptor Blockers 
Victor L. Serebruany, Alex I. Malinin. David R. Lowry, David C. Sane, Randy L. Webb, 
Sidney 0. Gonlieb. Charles H. Hennekens, Sinai Hospital, Johns Hopkins University, 
Baltimore, MD, University of Miami, Miami, FL 
Background: Valsartan (V) selectively blocks angiotensin II binding to the AT, receptor. 
Since platelet activation plays a key role in the pathogenesis of coronary and cerebrovas- 
cular occlusion, and since AT, receptors are present on the platelet surface, we 
assessed the in vitro effects of V and its metabolite, valeryl 4.hydroxy valsartan (V4HV), 
on platelets in 20 subjects with multiple vascular disease risk factors. Methods: Platelet 
characteristics in blood samples pretreated and incubated with 10 nmol to 100 wmol con- 
centrations of V and V4HV were assessed by conventional and whole blood aggregome- 
try. Closure time, platelet activation units, platelet-bound fibrinogen, and platelet- 
leukocyte formation also were measured, as well as expression of platelet receptors 
using several monoclonal antibodies. Results: Pretreatment of blood with V and V4HV 
resulted in inhibition of conventional (ADP: k.0002, V; epinephrine: f=.OOOl, V4HV) 
and collagen-induced (E.02, V; P=.OOOi, V4HV) platelet aggregation. Expression of 
many monoclonal antibodies and platelet-bound fibrinogen was significantly reduced 
compared with autologous baseline activity. Closure time was delayed (E.02, V; e.03, 
4VHV), indicating platelet inhibition in whole blood under high shear conditions. Intensity 
of platelet-leukocyte formation and platelet activation remained unchanged. Platelet inhi- 
bition was not dose-dependent and was more potent for 4VHV than V in the therapeutic 
range. Conclusions: Valsartan and 4VHV exhibited significant in vitro inhibition of 
human platelets. Their antiplatelet properties appear to be independent of those of other 
antiplatelet agents. Whether valsartan reduces vascular ischemic events via additional 
pathways of platelet inhibition in patients with myocardlal infarction and ischemic stroke 
reqwes further research. 
1203-126 The Relationship Between Angiotensin Converting 
Enzyme Gene Polymorphism and Hypertensive 
Retinopathy 
Nezihi Baris, Ozer Badak, Ozgur Aslan. Onder Kirimli, Ozhan Goldeli, Bahri Akdeniz, 
Sema Guneri, Dokuz Eylul University, Izmir. Turkey 
Background: Retlnopathy is the important complication and major target organ damage 
of hypertension. We aimed to investigate the relationship between angiotensin convert- 
ing enzyme (ACE) gene polymorphism and hypertensive retmopathy. 
Methods: Fifty-one patients (31 female, mean age:53,3 r 9 years) with essential hyper- 
tension were enrolled in this study. Patients with diabetes mellitus were excluded. Hyper- 
tensive retinopathy was diagnosed in dark room with direct ophtalmoscopy by an 
ophtalmalogist blinded to climcal data. Polymerase chain reaction was used to detect the 
insertion/deletion (l/D) polymorphism of the ACE gene. Statistical analysis was per- 
formed using the chi-square and analysis of variance methods. 
Results: Basal characteristics of the patients were similar in groups. The significant dif- 
ferences were found among these groups.(Table) 
Table 
ACE Genotype 
Retinopathy DD (n=20) DI (w24) II (n=7) P 
Yes 20 (%lOO) 14 (%60,9) 2 (%28,6) <0,0001 
No 0 (%O) 9 (%39.1) 5 (%71,4) <0,0001 
Conclusion: Hypertensive patients with D allel of ACE gene represent a tendency to 
hypertensive retinopathy. Identification of ACE genotype in hypetlensive patients might 
be useful to discriminate the patients who are more susceptible to hypertensive retinopa- 
thy 
1203-l 29 Safety of the Centrally Acting Wake-Promoting Agent 
Modafinil in Hypertensive Sleep Apnea Patients 
Jonathan Sackner-Bernstein, S. Arora, Craig Q. Earl, St. Luke’s_Roosevelt Hospital 
Center, New York, NY, Cephalon Inc., West Chester, PA 
Background. Obstructive sleep apnea (OSA) IS common in patients with cardiovascular 
disease and contributes to hypertension (HTN) and sympathetic nervous system activa- 
tion. The centrally-acting wake-promoting agent modafinil reduces excessive daytime 
sleepiness (EDS) and improves quality of life (QOL) when used adjunctively in OSA. 
Because of theoretical risk of CNS stimulants in cardiovascular disease, we evaluated 
the cardiovascular effects of modafinil in OSA patients with current or past history of 
HTN. 
Methoda Effects on heart rate (HR) and systolic and diastolic blood pressure (BP) mea- 
sured at rest and clinical experiences during therapy were determined from 3 random- 
ized, double blind, placebo-controlled trials of modafinil for OSA (2-l 2 weeks of therapy 
with placebo, 200 or 400 mg qd, n=218. 109, 214 respectively). HTN was defined by cur- 
rent therapy or the diagnosis of HTN currently or in the past. 
Reeulta 274 HTN patients were middle aged (52 yrs) obese (BMl=36.3) Caucasian 
(87%) men (79%) with BP of 130/81. In HTN group, modafinil did not increase BP 01 HR, 
nor were there differences in clinical cardiovascular adverse effects. Combining HTN 
with non-HTN revealed similar lack of effect on BP and HR by modafinil 200 mg or 400 
JACC March 19,2003 ABSTRACTS - Vascular Disease, Hypertension, and Prevention 3 11A 
mg relative to placebo. 
Conclusions In addition to reducing EDS and improving QOL for patients with OSA, 
modafinll does not wcrsen BP in patients with HTN. The lack of change in HR suggests 
that modafinil may decrease the sympathetic activation seen in HTN patients with OSA. 
Effects on BP and HR in HTN (* denotes sigmiicant change from baseline) 
HTN group Placebo 200mg 400mg 
Systolic BP baseline 130.8 * 12.6 131.5* 12.7 128.1 * 12.2 
Systolic BP change -2.1 * 12.3’ -3.4 * 15.3 1.8 *13.4 
Diastolic BP baseline 80.9 * 8.1 81.9 * 7.9 80.0 +7.6 
Diastolic BP change -2.2 r 8.8’ -3.9 * 9.1’ 0.9 * 9.2 
HR baseline 70.4 * 9.5 70.5*11.1 72.4 + 9.9 
HR change 0 * 9.6 -0.04 * 10.5 0.9 * 10.8 
1203-l 30 Relationship of Platelet P-Selectin Levels and Platelet 
Morphology to Platelet Activation in Hypertensives 
Sunil K. Nadar. Sridhar kamath, Andrew Blann, Gregory Y. Lip, City Hosptial, 
Birmingham, United Kingdom 
Background: Platelet activation occurs in hypertension. We undertook this study to eval- 
uate the relation of platelet levels of the adhesion molecule P-selectin to platelet activa- 
tion and platelet morphology in high risk hypertension. 
Methods: We studied platelet parameters from 199 consecutive patients with high risk 
hypertension and 59 age and sex matched normotenslve ccntrols. Platelet P-selectin in 
the three groups was measured by the lysate technique. 
Results: There was significant difference in platelet parameters in patients with hyperten- 
sion and normotensive controls ITablet]. Subgroup analysis of the hypertensive group 
showed that patients on aspirin had lower platelet [96.3 (57-130) x 10 * ng/platelet vs 
105.4 (84.143) x lo6 ng/platelet; p=O.O3] and soluble P-selectin[l35 (101-190) ng/plate- 
let vs 159.2 (118.5 -227) ngl platelet; p=O.Ol] than those who were not on aspirin. Other 
drugs such as calcium channel blockers and statins did not influence these parameters, 
nor did factors such as diabetes or smoking. 
Conclusions: Hypertensive patients have platelets that appear to be larger and heavier 
than platelets from normotensive healthy controls. The increase in P- selectin values per 
platelet could further represent a heightened state of activation, which IS reduced with 
aspirin. 
Table 1: 
Age 
Male/Female 
SBP 
DBP 
Mean platelet volume (fl) 
PDW- Platelet distribution 
width(%) 
Mean platelet concentration(g/dl) 
Mean platelet mass(pg) 
Soluble p-selectin (@ml) 
Platelet P-se&tin (xl0 -6 ng/ 
platelet) 
beta thromboglobulin (IUirnl) 
*- Median(interquartile range) 
All other figures are mean (S.D) 
Controls 
n=59 
68.4 (11.01) 
41/18 (69.4%/ 
30.6%) 
130(9.9) 
80.5(9) 
6.36 (0.9) 
46.4(5.6) 
29(2.3) 
1.76(0.17) 
77 (38-l 10)’ 
78.3 (47-120) * 
100 (57.282) * 
Hypeltensives P 
II=199 value 
67.9 (9.9) 0.7 
151148 (75.90~1 0.3 
24.1%) 
147(22) 0.001 
80.1(11) 0.9 
7.8 (3.03) 0.005 
55.1(8.4) co.001 
27.1(2.5) <O.OOl 
1.9(0.21) <O.OOl 
150(106.8-213)‘ c0.001 
99.6 (73.2-138.5) * 0.004 
306.6(210-354) * <O.col 
1203-131 Accelerated Coronary Artery Calcification in Mildly 
Reduced Renal Function of High-Risk Hypertensives: A 
Three-Year Prospective Observation 
Joseph Shemesh, Michael Bursztyn. Ehud Grossman, Michael Mqtro, Cardiac 
Rehabilitation Institute, Sheba Medical Center, Israel, Hadassah University Hospital, 
Mount Scopus, Jerusalem, Israel 
Background: Patients with end stage renal disease have accelerated coronary artery cal- 
cifications. However the effect of mild renal dysfunction has not been described. 
Methods: We examined the progression of coronary atherosclerosis as measured by 
dual-section spwal computed tomography using the total coronary artery calcium score 
as a quantitative measure of the burden of atherosclerosis. Of the 547 high-risk hyper- 
tensive patients participants of the prospective calcification study, a side arm of the inter- 
national INSIGHT study, 313 patients completed the 3 years follow-up. Subjects were 
studied upon entry (on placebo) and again after 3 years of treatment (nifedipine or thiaz- 
ide). Patients were divided to 2 groups depending on their creatinine clearance: zZiOml/ 
rnln renal dysfunction (RD) (n=53), and >GOmVmin-normal renal function group (11~263). 
Results: Blood pressure, hypercholesterolemia, and smoking did not differ between the 
groups. After 3 years of treatment blood pressure control was similar, whereas the total 
coronary artery calcium score progression was 2 fold greater in the RD than the normal 
group, 156i32 vs. 64&. respectively, p=O.O06. In a multiple logistic regression analysis 
the odds ratio (OR) for total coronary artery calcium score progression was higher for the 
RD group: 2.1 with 95%confidence interval (Cl) of 1.2-3.7. Gender, body mass index, 
smoking, cholesterol, family history of IHD, and diabetes were not significant predictors. 
Thiazide based antlhypertensive therapy predicted a faster progression compared to 
nifedipine, OR 1.66 95% Cl 1.09-2.51. 
Conclusion: Mild renal dysfunction accelerates coronary artery calcifications, above and 
beyond conventional risk factors. Nifedipine may have a protective role. 
1203-l 32 An Affected Pedigree Member Analysis of the Linkage 
Between the Taql Polymorphism of the Dopamine D2 
Receptor Gene and Obesity-Related Hypertension in 
Hong Kong Chinese 
Yu-Jina Fang G. Neil Thomas, i’ong-Li Xu, Ji-Qian Fang, Brian Tomlinson, Chinese 
University of Hong Kong. Shatin, Hong Kong, Sun Yat-Sen University of Medicine 
Science, Guangzhou, People’s Republic of China 
Background: Dopamine modulates a variety of physiological functions including natri- 
uresis and satiety. We have previously reported that the Taql polymorphism of the 
dopamine D2 receptor (DDPR) gene is associated with both blood pressure and obesity 
indices in a normoglycaemic Hong Kong Chinese population. In this study, we present 
evidence confirming the linkage between this gene polymorphism and obesity-related 
hypertension. 
Methods: Family members of 96 normoglycaemic hypertensive subjects were recruited, 
including 281 siblings, of which 133 were hypertensive. Central obesity was defined as a 
waist-to-hip ratio oft0.9 and20.85 in males and females respectively, and was identified 
in 98 of the siblings. The DDPR gene Taql polymorphism was identified with a poly- 
merase chain reaction based restriction fragment length polymorphism protocol. Affected 
pedigree member linkage analysis (sib-pair program, version 0.99.9, by DL Duffy) was 
used to assess for linkage between this gene polymorphism and obesity-related hyper- 
tension. 
Results: Linkage analysis was used to analyze 73 families with siblings discordant for 
hypertension. Based on the data of 133 hypertensive siblings, 69 central obese hyper- 
tensive siblings and 118 non-obese normotensive siblings, the Al allele frequencies 
were similar at 0.431, 0.426 and 0.429 respectively. Affected pedigree member linkage 
analysis suggested that the DDPR gene Taql polymorphism had significant linkage with 
blood pressure (t-1.86, p=O.O13) as well as obesity-related hypertension (t=-1.58. 
p=0.007). 
Conclusions: Our data in normoglycaemic Hong Kong Chinese supports that the DDPR 
gene Taql polymorphism is a marker associated with the pathogenesis of obesity-related 
hypertension. 
1203-133 Treatment Patterns and Goal Attainment Among 
Hypertensive Patients With and Without Dyslipidemia 
and/or Diabetes 
J. Sanford Schwartz. Trent McLaughlin, Deborah Griffis, Amy Arnold, Daniel Penitt, NDC 
Health, Phoenix, AZ, Pfizer. Inc., New York, NY 
Backgrounrt The purpose of this analysis was to determine treatment patterns among 
hypertenswe patients with either dyslipidemia (DL) or diabetes (DM) and assess the pro- 
portion that reach blood pressure goal versus those with hypertension (HTN) alone. 
Methods: Retrospective analysis using the GE Medical MQIC database. This database 
consists of electronic medical records collected from 8 primary care sites around the 
United States. Patients with a diagnosis and/or clinical evidence (defined as meeting 
JNC-VI hypertension or NCEP-ATPIII guidelines) were identified and followed throughout 
2001. Patients were stratified based on the presence of either DL or DM. Patients were 
further required to have received pharmacotherapy and have 21 recorded blood prss- 
sure tc determine goal status. Blood pressure goal was defined as meeting the goal set 
by JNC-VI or ADA, after accounting for patient risk factors. 
ResuItS: Of the 41,417 hypertensive patients included in the analysis, approximately 
47% also had DL and/or DM. As shown below, although patients with multiple conditions 
were mere likely to be receiving multiple antihypertensive drugs (AHDs) compared to 
patients with HTN alone, there were significantly less likely to achieve blood pressure 
goal. 
Conclusions Despite receiving mere antihypertensive medications, patients with multi- 
ple conditions were significantly less likely to achieve blood pressure goal during the 
study period. 
N At Blood Pressure Drug Classes 
Goal 
1 AHD 2AHDs 3+ AHDs 
HTN alone 21.807 37.2% 47.7% 27.2% 25.0% 
HTN+DL 12,687 30.2%’ 39.0% 28.7% 32.3% 
HTN+DM 2,261 30.2%’ 31.4% 25.7% 42.8% 
HTN+DL+DM 4,662 29.9%’ 29.3% 26.0% 44.7% 
‘~0.001 vers”s HTN alone 
AHD = Antihypertenswe drug 
